These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 38426102)

  • 1. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management.
    Lin MX; Zang D; Liu CG; Han X; Chen J
    Front Immunol; 2024; 15():1266850. PubMed ID: 38426102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond.
    Reuss JE; Suresh K; Naidoo J
    Curr Oncol Rep; 2020 May; 22(6):56. PubMed ID: 32415399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
    Zhou P; Zhao X; Wang G
    Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors.
    Shibata Y; Murakami S; Kato T
    Expert Opin Drug Saf; 2021 May; 20(5):537-547. PubMed ID: 33650443
    [No Abstract]   [Full Text] [Related]  

  • 5. Pulmonary toxicities of immune check point inhibitors in the management of cancer: mini review.
    Jayakrishnan B; Al-Moundhri M; Burney I; Al-Hashami Z; Al-Bimani K
    Adv Respir Med; 2022; 90(3):219-229. PubMed ID: 35731114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
    Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).
    Hu X; Ren J; Xue Q; Luan R; Ding D; Tan J; Su X; Yang J
    Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37681488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
    Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
    BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
    Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
    Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
    Zhang Q; Tang L; Zhou Y; He W; Li W
    Front Immunol; 2021; 12():663986. PubMed ID: 34122422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Establish a whole-process comprehensive surveillance management mode for immune checkpoint inhibitor pneumonitis].
    Xu Y; Pan RL; Huang H; Wang MZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Aug; 57(8):1176-1180. PubMed ID: 37574309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.
    Li X; Yang F; Liu B; Ye L; Du J; Fan X; Yu Y; Li M; Bu L; Zhang Z; Xie L; Li W; Qi J
    J Immunother; 2024 Jul-Aug 01; 47(6):220-226. PubMed ID: 38618919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
    Lin X; Lu T; Li S; Xie X; Chen X; Jiang J; Qin Y; Xie Z; Liu M; Ouyang M; Zhong N; Song Y; Zhou C
    Clin Transl Oncol; 2021 Feb; 23(2):389-396. PubMed ID: 32613413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.
    Wang W; Wang Q; Xu C; Li Z; Song Z; Zhang Y; Cai X; Zhang S; Lian B; Li W; Liu A; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Xie C; Zhang J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Lan F; Feng H; Wang L; Yao W; Shi X; Huang J; Chen H; Zhang Y; Sun P; Wan B; Pang F; Xu Z; Wang K; Xia Y; Ye M; Wang D; Wei Q; Feng S; Zhou J; Zhang J; Lv D; Gao W; Kang J; Yu G; Liang X; Yu C; Shi L; Yang N; Wu L; Hong Z; Hong W; Fang M; Zhang Y; Lu Y; Wang G; Ma S; Si L; Fang W; Song Y
    Thorac Cancer; 2022 Dec; 13(23):3420-3430. PubMed ID: 36268845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.
    Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C
    Front Immunol; 2021; 12():818492. PubMed ID: 35095920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
    Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H
    Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
    Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
    J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and chest CT features of immune checkpoint inhibitor-related pneumonitis].
    Zhang Q; Zhao SJ; Wang SH; Tao XL; Wu N
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):182-187. PubMed ID: 36781241
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
    Fujiwara Y; Horita N; Namkoong H; Galsky MD
    Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.